Key Highlights What is Liraglutide? Liraglutide is a GLP-1 receptor agonist, a class of medications revolutionizing type 2 diabetes treatment and weight loss management. Marketed as Victoza for diabetes and Saxenda for obesity, it mimics the GLP-1 hormone to regulate blood sugar and suppress appetite. Approved in the US since 2010, it’s a go-to option … Read more
Leading the charge is retatrutide, a next-generation obesity drug developed by Eli Lilly that’s generating unprecedented excitement. Dubbed the “triple agonist,” retatrutide targets three hormonal pathways simultaneously, offering not just significant weight loss but also metabolic benefits that could revolutionize obesity care.
Key Highlights: A New Hope for Obesity and Diabetes Obesity and type 2 diabetes (T2D) are global health crises, affecting 1 billion and 537 million adults worldwide, respectively . Orforglipron, an oral GLP-1 receptor agonist developed by Eli Lilly, offers a groundbreaking solution. Unlike injectable alternatives, this pill-based medication simplifies treatment, making it more accessible and user-friendly. This blog … Read more
Projected 1 Billion Obese by 2025 (WHO) Childhood Obesity Doubles to 390 Million (2020–2025) U.S. Adult Obesity at 40.3% (2023) Economic Toll of $2 Trillion by 2025 Racial Disparities in U.S. Obesity Obesity Linked to 50% of New Diabetes Cases Rural U.S. Obesity Rates at 40% Education’s Role in Obesity Rates Military Readiness at Risk … Read more
